top of page
  • Recruiting

NCT04017130: Phase 1: Study to Evaluate the Safety, Tolerability, Pharmak & Efficacy of MT-0169 RRMM

Updated: May 26, 2022

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MT-0169 in Patients With Relapsed or Refractory Multiple Myeloma or Non-Hodgkin Lymphoma


MT0169

This will be a Phase 1 Open-Label, dose escalation and expansion study of MT-0169 (an Engineered toxin body (ETB) in patients with relapsed or refractory multiple myeloma or non-Hodgkin lymphoma. MT-0169 is an investigational drug that recognizes and binds to the CD38 receptor, which may be found on the surface of multiple myeloma and non-Hodgkin lymphoma cancer cells. It delivers a dose of a modified toxin that kills these cells.


Sponsor

Molecular Templates, Inc


Multiple Locations

 

ClinicalTrials.gov Identifier: NCT04017130


Official Title: A Phase 1, Open-Label, Dose-Escalation and Expansion, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MT-0169 in Patients With Relapsed or Refractory Multiple Myeloma or Non-Hodgkin Lymphoma


First Posted : July 12, 2019


Click here for details on ClinicalTrials.gov


Click here for details on cancer.gov

 

Drug: MT-0169

Specifically Engineered to Eliminate CD38 Expressing Cells

 

Locations

United States, California

United States, Florida

United States, Indiana

United States, Minnesota

United States, Pennsylvania

United States, Tennessee



Posts Archive
bottom of page